

Technical Information

Hisitest Agar

Product Code: DM 1485A

Application: - Hisitest Agar is used for determination of antibiotic susceptibility of fastidious microorganisms.

Composition**

Ingredients	Gms / Litre	
Casein enzymic hydrolysate	11.000	
Peptone	3.000	
Sodium chloride	3.000	
Dextrose	2.000	
Starch	1.000	
Buffer salt	3.300	
Nucleoside basis	0.020	
Thiamine	0.00002	
Agar	8.000	
Final pH (at 25°C)	7.4±0.2	
**Formula adjusted, standardized to suit performance parameters		

Principle & Interpretation

Hi-Sensitivity Test Agar is developed for antimicrobial susceptibility tests It gives a reproducible, semi-defined medium in which the mineral contents have been stabilized. The thymine and thymidine content is very low thus making it most suitable for testing antimicrobial activity of sulphonamides. It supports the growth of majority of micro-organisms without further supplementation. Casein enzymic hydrolysate, peptone, dextrose, vitamins supply nitrogen, carbon compoundsand other essential growth nutrients.

This medium has been designed to overcome the problems occurring in Mueller-Hinton media as (1 - 7)

- 1. Different M.I.C. values in the broth and agar versions of the medium.
- 2. Agar shows antagonistic effect towards tetracycline.
- 3. High levels of sulphonamide and trimethoprim antagonists.
- 4. Poor reproducibility with different manufacturers peptones.
- 5. Poor growth supporting ability for Streptococci and variable growth rates with Gram-positive organisms.

Some mutant strains which are totally dependent on thymine and thymidine for their growth, will not grow on Sensitivity Test Agar due to very low levels of these compounds in this medium as they are the naturally occurring antagonist of Trimethoprim. Care must be taken to recognize these strains (8, 9, 10). Some pathogenic organisms are nutritionally dependent due to intrinsic demands for special growth factors. Supplemental nutrients can be added to Sensitivity Test Agar to improve the growth of these organisms (1). The following nutrients can be used.

Nutrient	Micro-organisn
Nutrient	iviici 0-0i gailisii

1. Laked Blood (5% v/v) Neisseria and Streptococcus 2. Fildes Peptic Digest of Blood (5% v/v) Haemophilus

3. Menadione (0.5 mcg/ml) & Thiamine (2mcg/ml) Dwarf colonies of S.aureus and coliform bacteria

4. Pyridoxine Hydrochloride (1mcg/ml) Symbiotic Streptococci





Methodology

Suspend 31.32 grams of dehydrated powder media in 1000 ml distilled water. Mix thoroughly & heat to boil to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool to 45-50°C. Shake well before pour into sterile Petri

Quality Control

Appearance

Light yellow coloured homogeneous free flowing powder

Gelling

Firm, comparable with 0.8% Agar gel.

Colour and Clarity

Light yellow coloured clear to slightly opalescent gel forms in Petri plates.

Reaction

Reaction 3.13% w/v aqueous solution at 25°C. pH: 7.4±0.2

pH Range

7.20-7.60

Cultural Response

DM 1485A: Cultural characteristics observed after an incubation at 35 - 37°C for 18 - 24 hours.

Organism	Inoculum (CFU)	Growth	Recovery
Bacillus subtilis ATCC 6633	50-100	good-luxuriant	>=70%
Bacteroides vulgatus ATCC 8482	50-100	good-luxuriant	>=70%
Enterococcus faecalis ATCC 29212	50-100	good-luxuriant	>=70%
Salmonella Typhimurium ATCC 14028	50-100	good-luxuriant	>=70%
Staphylococcus aureus ATCC 25923	50-100	good-luxuriant	>=70%
Streptococcus pyogenes ATCC 19615	50-100	good-luxuriant	>=70%

Storage and Shelf Life

Dried Media: Store below 8°C in tightly closed container and the prepared medium at 2-8°C. Use before expiry date on the label. **Prepared Media:** 2-8° in sealable plastic bags for 2-5 days.

Further Reading

- 1. Ericsson H.M. and Sherris J.C., 1971, Acta. Pathol. Microbiol., Scand Suppl., 217:1.
- 2. Garrod L.P. and Waterworth P.M., 1971, J. Clin. Path., 24:779.
- 3. Reller L.B., Schoenknecbt F.D., Kenny M.A. and Sherris J.C., 1974, J. Infect. Dis., 130:454.
- 4. Duncan I.B.R., 1974, Antimicrobial agents & Chemotherapy, 5:9.
- 5. Yourassowsky E., Vanderlinden M.P. and Schoutens E., 1974, J. Clin. Path 27:897.
- 6. Neussil H., 1976, Chemotherapy, Vol. 2:33.
- 7. Bridson E.Y., 1976, Arztl. Lab. 22:373.
- 8. Tanner E.I. and Bullin C.H., 1974, J. Clin. Path., 27:565.
- 9. Thomas M. and Bond L., 1973, Med. Lab. Technol., 30:277.
- 10. Barker J., Healing D. and Hutchinson J.G.P., 1972, J. Clin. Path., 25:1086.





Disclaimer:

- User must ensure suitability of the product(s) in their application prior to use.
- The product conform solely to the technical information provided in this booklet and to the best of knowledge research and development work carried at CDH is true and accurate
- Central Drug House Pvt. Ltd. reserves the right to make changes to specifications and information related to the products at any time.
- Products are not intended for human or animal diagnostic or therapeutic use but for laboratory, research or further manufacturing of diagnostic reagents extra.
- Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents. Do not use the products if it fails to meet specification for identity and performance parameters.

